ADReCS

Pharmaceutical Information

Drug Name	Crizotinib
Drug ID	BADD_D00535
Description	Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
Indications and Usage	Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
Marketing Status	approved
ATC Code	L01ED01
DrugBank ID	DB08865
KEGG ID	D09731
MeSH ID	D000077547
PubChem ID	11626560
TTD Drug ID	D03ZBT
NDC Product Code	68724-1020; 53869-2231; 53869-2230; 0069-8140; 0069-8141
UNII	53AH36668S
Synonyms	Crizotinib \| PF-02341066 \| PF-2341066 \| PF 2341066 \| PF2341066 \| PF 02341066 \| PF02341066 \| Xalkori

Chemical Information

Molecular Formula	C21H22Cl2FN5O
CAS Registry Number	877399-52-5
SMILES	CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Pericarditis	02.06.02.001	0.000224%
Periorbital oedema	06.08.03.017; 10.01.05.010; 23.04.01.002	-	-
Peripheral coldness	08.01.09.010; 23.06.04.008; 24.04.03.006	0.000437%		-
Peripheral sensory neuropathy	17.09.03.005	0.000381%
Phlebitis	12.02.01.002; 24.12.03.004	0.000112%
Photophobia	06.01.01.004; 17.17.02.006	0.001970%
Photopsia	06.02.06.004; 17.17.01.006	0.007656%
Photosensitivity reaction	23.03.09.003	0.001366%
Pleural effusion	22.05.02.002	0.006078%
Pleurisy	22.05.01.001	0.000280%		-
Pneumonia	11.01.09.003; 22.07.01.003	-	-	-
Pneumonitis	22.01.01.006	0.007264%
Pneumothorax	22.05.02.003	0.000672%
Polyneuropathy	17.09.03.012	0.000112%		-
Productive cough	22.02.03.005	0.000582%
Pulmonary alveolar haemorrhage	22.01.02.005; 24.07.01.015	0.000112%		-
Pulmonary embolism	22.06.02.001; 24.01.06.001	0.003492%		-
Pulmonary haemorrhage	22.12.01.009; 24.07.01.016	0.000224%
Pulmonary oedema	02.05.02.003; 22.01.03.003	0.001858%
Pyrexia	08.05.02.003	-	-
Rash	23.03.13.001	-	-	-
Renal cyst	16.27.01.001; 20.01.04.001	0.001948%		-
Renal disorder	20.01.02.002	0.001052%		-
Renal failure	20.01.03.005	0.003548%		-
Renal haemorrhage	12.01.05.004; 20.01.02.013; 24.07.07.002	0.000112%
Renal vein thrombosis	20.01.07.011; 24.01.11.002	0.000168%		-
Respiratory disorder	22.02.07.002	0.000660%		-
Respiratory distress	22.02.01.012	0.000392%		-
Respiratory failure	14.01.04.003; 22.02.06.002	0.001925%
Retching	07.01.07.002	0.000817%		-

The 7th Page First Pre 7 8 9 10 11 Next Last Total 13 Pages